Muscular dystrophy refers to more than 30 genetic conditions that cause progressive muscle weakness. Duchenne muscular dystrophy is the most common childhood form, affecting about 1 in 5,000 boys. Treatment has historically focused on managing symptoms and complications, but genetic therapies are now reaching patients.
What's actually going on in research
Trials are testing gene therapies that deliver a working copy of the dystrophin gene, exon-skipping drugs that restore partial dystrophin production, and drugs that boost utrophin to compensate for missing dystrophin. Corticosteroids remain standard treatment for Duchenne, and newer anti-inflammatory approaches aim to preserve muscle function with fewer side effects. Research also targets other dystrophy types, including limb-girdle and facioscapulohumeral muscular dystrophy.
Gene therapy
Several gene therapies are delivering a miniaturized dystrophin gene to muscle cells. Early results show some patients producing detectable dystrophin protein, though durability and functional benefit are still being studied.
Exon skipping
Four exon-skipping drugs are FDA-approved for Duchenne, each targeting different genetic mutations. New exon-skipping candidates aim to help a larger proportion of patients and produce more dystrophin protein.
Anti-inflammatory drugs
Researchers are testing alternatives to corticosteroids that might preserve muscle without causing weight gain, bone loss, and growth problems. Vamorolone showed promise in early trials.
What to know before you search
Eligibility typically depends on genetic mutation type, whether the person is still walking, heart and lung function, prior treatments including steroids, and sometimes age or antibody status for gene therapies.
What types of trials are currently open
- Gene therapy trials — Testing one-time infusions that deliver genetic material to muscle cells. These trials typically require heart and lung function above minimum thresholds.
- Exon-skipping trials — Testing drugs that modify how genetic instructions are read, allowing cells to produce a shortened but partially functional dystrophin protein.
- Drug trials — Testing medications that reduce inflammation, boost muscle growth, or protect heart and breathing muscles from damage.
- Natural history studies — Tracking how muscular dystrophy progresses over time to establish baselines for measuring whether new treatments slow decline.
- Biomarker studies — Looking for blood tests or imaging markers that could predict disease progression or treatment response.
Recently added Muscular Dystrophy trials
Take a nutritional supplement designed for Duchenne muscular dystrophy
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
Share stored blood and muscle samples to advance muscular dystrophy research
This is a monocentric, no-profit, retrospective and prospective observational cohort study conducted at IRCCS Ospedale San Raffaele. The study does not entail any additional procedures or interventions for participants. Biological samples (including blood/serum and muscle biopsies) are obtained for a previously approved study (LAMA2\_GUP24002) and collected under the existing BancaINSpe informed consent. For the present study, analyses will be performed on biospecimens already stored or that will be stored at BancaINSpe, using portions of material already collected for the LAMA2\_GUP24002 protocol.
Find Muscular Dystrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.